{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/anticoagulation-oral/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"31157a72-4e11-5ad4-8139-919ce4241f22","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 93a35716-5052-4530-9a55-b5445a549cd4 --><h2>Changes</h2><!-- end field 93a35716-5052-4530-9a55-b5445a549cd4 -->","summary":null,"htmlStringContent":"<!-- begin item d194baa4-4ea1-45eb-a5dc-f57159b63403 --><!-- begin field 1fc7e92a-9825-482f-868e-24759a2f8e81 --><p><strong>January 2021</strong> — reviewed. A literature search was conducted in December 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. No major changes to clinical recommendations have been made. However, sections on monitoring people taking anticoagulants during the COVID-19 pandemic has been included, based on the Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update <em>Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic</em> [MHRA, 2020].</p><!-- end field 1fc7e92a-9825-482f-868e-24759a2f8e81 --><!-- end item d194baa4-4ea1-45eb-a5dc-f57159b63403 -->","topic":{"id":"5e046307-14e1-50a6-9729-69af5ae00b78","topicId":"d64523b7-19f2-41a0-afd4-d1c0790cce30","topicName":"Anticoagulation - oral ","slug":"anticoagulation-oral","lastRevised":"January 2021","chapters":[{"id":"b5dcda3e-cc4c-56b5-9348-00f8e8eb8e32","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2424a367-7b32-59ea-8783-9d80a1a68c3c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"02a83663-a0e4-533a-a0a3-a6b15235867c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"31157a72-4e11-5ad4-8139-919ce4241f22","slug":"changes","fullItemName":"Changes"},{"id":"14f1139a-434d-530b-be52-9692e9271a76","slug":"update","fullItemName":"Update"}]},{"id":"67dfc47b-2285-596f-9f26-279a85f25dcc","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"a4b943e8-803b-51b4-a154-3a58c4bbaf1a","slug":"goals","fullItemName":"Goals"},{"id":"1a8fff43-5d5a-5e06-803b-ea61542c56a4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a1c4ef1a-272a-56c2-bba9-b437e8b0e03d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"54bcfbdc-7506-5ca1-ae0c-e5ab55acb001","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"2387aba8-f14a-5fc6-8335-485e08a6c959","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"dd9aca34-523a-570a-bb3f-422e7bf450a7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"772f3b00-3aa4-5b51-aad4-43ff44e987d3","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e9b14f86-2066-57e8-9b9f-65926e978b59","slug":"mode-of-action","fullItemName":"Mode of action"},{"id":"55f43edd-e0fd-5e66-a53b-36ef8f137cd3","slug":"licensed-indications","fullItemName":"Licensed indications"}]},{"id":"1432aebe-6008-53bc-915b-8f136a3cc1e6","fullItemName":"Management","slug":"management","subChapters":[{"id":"46bb380b-6d51-5ede-b5dc-78ec7987f404","slug":"apixaban","fullItemName":"Scenario: Apixaban"},{"id":"e4a2d921-e87f-5760-a17a-271fefa9d1c4","slug":"dabigatran","fullItemName":"Scenario: Dabigatran"},{"id":"e0aace92-5b9a-53c2-af09-6318f0911654","slug":"edoxaban","fullItemName":"Scenario: Edoxaban"},{"id":"015cbcc5-4efe-568f-9643-d7a22d37b286","slug":"rivaroxaban","fullItemName":"Scenario: Rivaroxaban"},{"id":"693e35a4-4b44-514c-847c-855a53793f98","slug":"warfarin","fullItemName":"Scenario: Warfarin"}]},{"id":"3d346e04-bfd5-53aa-9cbe-bee5c6a912bb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"76dbe1dd-0d3b-50e8-9472-5af55550c77a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"5f762de3-78b6-55d7-b9bb-cc3f1cb77bea","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0c725a38-4d35-5fbd-bd5d-b48afc70e783","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2b9eb7d5-9bc8-5af8-b91f-75e9b1480d83","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"33630559-9216-56bf-9890-6bbe997245bc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51bd3b51-3e20-5f51-a925-74b2c904fd53","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"54dbb8de-8bee-5c53-b63b-9645b55e6b5d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"02a83663-a0e4-533a-a0a3-a6b15235867c","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"d5d4f0df-f975-556c-adfd-43e15e3c554b","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field c56d2c4c-5a9f-4906-b47b-c6e4445c5236 --><h3>Previous changes</h3><!-- end field c56d2c4c-5a9f-4906-b47b-c6e4445c5236 -->","summary":null,"htmlStringContent":"<!-- begin item 3bccaa01-01a1-4157-b5c2-911e936ea712 --><!-- begin field e74051c7-2687-4c61-9bac-c28bfc7ed3f7 --><p><strong>September 2020 </strong>— minor update. Information on monitoring of people taking direct oral anticoagulants (DOACs) has been clarified. A link to a reference has also been updated. </p><p><strong>August 2020 </strong>— minor update. Dosage information for rivaroxaban has been clarified and angioedema added as an adverse effect of apixaban. </p><p><strong>July 2020 </strong>— minor update. Broken URL links updated.</p><p><strong>July 2020 </strong>— minor update. Dabigatran adverse effects updated in line with revised manufacturer's Summary of Product Characteristics (SPC).</p><p><strong>May 2020 </strong>— minor update. The section on Warfarin scenario has been updated to clarify that the target range for some conditions is 2.5.</p><p><strong>January 2020</strong> — minor update. Dose information for dabigatran was updated to clarify that treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults should be started following treatment with a parenteral anticoagulant for at least 5 days.</p><p><strong>June 2019</strong> — minor update. Apixaban is now known to be contraindicated in people with history of thrombosis diagnosed with antiphospholipid syndrome, especially in triple positive people, where use of DOACs could be associated with increased rates of recurrent thrombotic events.</p><p><strong>November 2017</strong> — minor update. Information added on concurrent use of apixaban with clarithromycin as per the updated manufacturer's SPC. </p><p><strong>July 2017</strong> — minor update. Added additional adverse effects of rivaroxaban as per the updated manufacturer's SPC. </p><p><strong>January 2017</strong> — minor update. Updated the topic in line with the Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update <em>Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR.</em></p><p><strong>October to November 2016</strong> — reviewed. A literature search was conducted in October 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. Information on edoxaban, a new DOAC, has been added to this topic. </p><p><strong>October 2015 </strong>— minor update. Angioedema, allergic oedema, cholestasis, hepatitis (including hepatocellular injury), and thrombocytopenia have been included as adverse effects of rivaroxaban as per the updated manufacturer's SPC.</p><p><strong>August 2015 </strong>— minor update. The information in the section on Managing dosing errors for rivaroxaban has been clarified.</p><p><strong>July 2015 </strong>— minor update. The dosing of apixaban and rivaroxaban for people with renal impairment has been changed to give creatinine clearance (CrCl) values (instead of estimated Glomerular Filtration Rates [eGFR]).</p><p><strong>February 2015 </strong>— minor update. The dabigatran section regarding dosage adjustments required for elderly people (80 years or older) and people prescribed verapamil has been updated in line with the National Institute for Health and Care Excellence (NICE) technology appraisal <em>Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism</em>.</p><p><strong>December 2014 </strong>— minor update. Prophylaxis of atherothrombotic events in adults with an acute coronary syndrome has been added as a licensed indication for rivaroxaban as per an update to the manufacturer's SPC.</p><p><strong>September 2014 </strong>— minor update. Minor typographical error corrected.</p><p><strong>August 2014 </strong>— minor update to the text to reflect the fact that apixaban is now licensed for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.</p><p><strong>July 2014 </strong>— minor update to the text to reflect the fact that dabigatran is now licensed for the treatment of DVT and PE, and prevention of recurrent DVT and PE in adults.</p><p><strong>May 2014 </strong>— minor update to the text to remove lettuce as a food that is high in vitamin K and replaced with kale.</p><p><strong>January 2014 </strong>— minor update. Minor typographical error regarding the ages in each of the scenarios has been fixed.</p><p><strong>October 2013 </strong>— minor update. A Drug Safety Update issued by the MHRA has clarified that contraindications for dabigatran where the person is at significant risk of major bleeding have also been applied to apixaban and rivaroxaban.</p><p><strong>May 2013 </strong>— reviewed. A literature search was conducted in March 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. Three new sections have been added to include the newer anticoagulants; apixaban, dabigatran, and rivaroxaban. Minor changes have been made to the recommendations for prescribing warfarin.</p><p><strong>November 2012 </strong>— minor update. The links to the electronic Medicines Compendium (eMC) website (<a href=\"http://www.medicines.org.uk/\" data-hyperlink-id=\"1920eebf-4f92-4182-9dae-a8f701562c69\">www.medicines.org.uk</a>) have been updated.</p><p><strong>May 2012 </strong>— minor typographical error corrected.</p><p><strong>March 2012 </strong>— minor update. The 2012/2013 Quality and Outcomes Framework (QOF) indicators have been added to this topic.</p><p><strong>December 2011 </strong>— minor update. Minor typographical error corrected. </p><p><strong>July 2011 </strong>— minor update. All references to the British Committee for Standards in Haematology (BCSH, 2011) guideline on oral anticoagulation with warfarin have been updated to reflect the latest guideline. Several sections within the topic have also been updated to reflect the guideline. </p><p><strong>April 2011 </strong>— minor update. Changes to text in line with Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>Drug interactions with hormonal contraception,</em> which states that an interaction between warfarin and hormonal contraception is unlikely.</p><p><strong>November 2010 </strong>— minor update. Advice regarding the effect of major changes in diet on anticoagulation has been reworded. </p><p><strong>January 2010 </strong>— minor update to include recent changes to warfarin safety information in the MHRA <em>Public assessment report. Warfarin: changes to product safety information.</em></p><p><strong>December 2009 </strong>— minor update. Advice on taking antidepressants in people receiving warfarin has been amended in the section on Drug interactions. Issued in December 2009.</p><p><strong>August to September 2009 </strong>— updated to include recommendations and supporting evidence on the place of self-testing and self-management of warfarin. Advice on the management of the drug interaction between selective serotonin reuptake inhibitors (SSRIs) and warfarin has also been added. </p><p><strong>July 2009 </strong>— updated to include target international normalized ratio (INRs) and duration of treatment for all indications for warfarin. A change to the recommendation on management of potential drug interaction between warfarin and macrolide antibiotics has also been made. </p><p><strong>December 2008 to March 2009 </strong>— this is a new CKS topic. The evidence base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field e74051c7-2687-4c61-9bac-c28bfc7ed3f7 --><!-- end item 3bccaa01-01a1-4157-b5c2-911e936ea712 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}